Thus, we sought (i) to report the prevalence of BRCA1/2 variants according to the pathogenicity level and in association with clinicopathological features; (ii) to evaluate the prevalence and the characteristics of somatic and germline alterations comparing tumor and blood BRCA test results; and (iii) to describe the clinically driven workflow for the management of EOC patients. Here, BRCA1 is linked to neoplasm.